RCS - N4 Pharma PLC - Establishment of New Senior Leadership Team

N4 PharmaAnnouncement

Tue 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250527:nRSa0805Ka&default-theme=true

RNS Number : 0805K  N4 Pharma PLC  27 May 2025

 

27 May 2025

 

N4 Pharma plc

 

("N4 Pharma" or the "Company")

 

Establishment of New Senior Leadership Team

 

N4 Pharma plc (AIM: N4P), the UK biotech developing Nuvec®, its proprietary
gene delivery system to enable advanced therapies for cancer and other
diseases, is pleased to announce the formation of a new Senior Leadership Team
comprising leading expert consultants in drug development and research,
commercial strategy, and pharmaceutical manufacturing.

 

The Senior Leadership Team will support the Board in delivering N4 Pharma's
strategic and scientific objectives set out by the Company at the recent
successful placing. The focus of the use of proceeds is to advance the
development of Nuvec® as a novel delivery platform and build out the
commercial data room in order to strengthen discussions with potential
commercial partners.

 

The Senior Leadership Team, which reports to the Chief Executive Officer, comprises the following members:

 

Dr Fiona McLaughlin - Head of Research and Development

Dr Fiona McLaughlin is a highly experienced oncology drug developer and
independent consultant, bringing over 25 years of experience in research and
translational drug development in the pharmaceutical and biotech sectors,
having led teams from early research through to clinical development. Fiona
started her career at GSK and has subsequently held leadership positions in
multiple biotech companies, including CSO of Avacta Therapeutics, VP New
Opportunities at Algeta ASA (now Bayer), VP Translational Research at Antisoma
plc and Director of Pre-clinical Development at BTG plc (now part of Boston
Scientific). She is also a non-executive director of Hox Therapeutics.

 

Fiona received a PhD from the Haematology Department at Cambridge University
and has a BSc in Biochemistry from Glasgow University.

 

Mark Edbrooke - Head of Strategy

Mark Edbrooke, PhD is an independent scientific consultant with a broad
experience in pharmaceutical research and development. During 25 years at
GlaxoSmithKline, he ran a transnational functional genomics department, and
then set up and led GSK's therapeutic nucleic acid unit. He then
joined AstraZeneca's Oncology Division for three years, working with Ionis
and Moderna.  Mark currently has a portfolio of clients, including UK and
US-based investment companies, UK and European-based universities, and
small biotechs, including being Head of Translational Research at Argonaute
RNA Ltd., and on the Senior Advisory Board for Deep Genomics.

 

Dr Simon Bennett - Commercial Director

 

Dr Simon Bennett is an independent consultant with over 28 years of experience
in the bio-pharma industry. Over the last 15 years, Simon has worked with more
than 70 clients of all sizes, from technology startups to Big Pharma, largely
supporting business development and licensing, as well as technology scouting
and fundraising.  Simon has been involved in over 80 commercial deals and
mentors and advises early-stage businesses and management teams, primarily in
specialty pharma and biotech.  Before moving into industry in 1997, Simon was
a Wellcome Trust Research Fellow at the University of Oxford.

 

Dr Margaret Courtney - Head of Chemistry, Manufacturing and Controls (CMC)

Dr Margaret Courtney is an independent consultant with over 25 years of
experience in transitioning active substances and drug products from the
research laboratory into clinical studies and commercialisation. Margaret has
worked in management positions in small biotech companies to large
pharmaceutical organisations, and following on from her pharmacy degree and
doctoral studies, has developed specific expertise in drug delivery systems.
Currently, she is working with a range of clients and providing CMC strategic
advice as well as selection and management of contract organisations.

 

Nigel Theobald, Chief Executive Officer of N4 Pharma, commented:

 

"The Senior Leadership Team that we have formed to help us swiftly deliver on
our strategic and scientific goals is a world-class group of consultants with
extensive experience in drug development, manufacturing and commercialisation.
These appointments bring essential expertise to advance the Nuvec® platform
towards our goal of commercial partnerships as well as build a pipeline of
novel, highly valuable RNA therapeutic concepts for N4 Pharma to develop
in-house.

 

"Each member of the Senior Leadership Team brings deep expertise and a proven
track record in their respective fields. Their involvement with N4 Pharma on
the development of Nuvec® is a strong endorsement of the progress to date and
a clear demonstration of confidence in its future potential.

 

"The Board looks forward to their valuable guidance as we continue to unlock
the full potential of Nuvec® as a novel delivery platform to enable advanced
therapies for cancer and other diseases."

 

- Ends -

 

For more information please contact:

 

 N4 Pharma plc

 Nigel Theobald, CEO                                                       Via N4 Pharma Investor Hub: investors.n4pharma.com

                                                                         (https://investors.n4pharma.com/)
 Luke Cairns, Executive Director

                                                                         https://investors.n4pharma.com/link/pegvRy
 Submit your questions directly to the management team via the N4 Pharma
 Investor Hub

 SP Angel Corporate Finance LLP                                            Tel: +44 (0)20 3470 0470

 Nominated Adviser and Joint Broker

 Matthew Johnson/Jen Clarke (Corporate Finance)

 Vadim Alexandre/Abigail Wayne/Rob Rees (Corporate Broking)
 Turner Pope Investments (TPI) Limited                                     Tel: +44 (0)20 3657 0050

 Joint Broker

 Andy Thacker

 James Pope
 Northstar Communications Limited                                          Tel: +44 (0)113 730 3896

 Investor Relations

 Sarah Hollins

 

About N4 Pharma

N4 Pharma is a pre-clinical biotech company developing Nuvec®, its
proprietary gene delivery system, to enable advanced therapies for cancer and
other diseases.

 

RNA therapeutics are set to impact the treatment of a wide range of diseases
and Nuvec® has several key advantages for RNA gene delivery including the
ability to deliver multiple RNA therapies in a single particle, ease of
manufacturing, protection of the RNA payload to allow for oral delivery, no
unwanted immune response and excellent stability and storage.

 

N4 Pharma is building out its preclinical data set and working towards
first-in-human clinical data to support significant licensing deals for its
Nuvec® platform with gene therapy partners.

 

N4 Pharma's lead programme, N4 101, is an oral anti-inflammatory product for
IBD which serves as a proof-of-concept programme showcasing all the benefits
of the Nuvec® platform.

 

For further information on the Company visit www.n4pharma.com
(http://www.n4pharma.com) or sign up at
https://investors.n4pharma.com/auth/signup
(https://investors.n4pharma.com/auth/signup) .

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRABGGDUISDDGUL